Discussion
Coya Therapeutics is approaching full enrollment in its main clinical trial for COYA 302, an experimental therapy for amyotrophic lateral sclerosis (ALS), having signed on its 100th participant. The Phase 2/3 ALSTARS trial (NCT07161999) aims to recruit 120 adults with ALS across sites in the U.S.